Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Nanoparticles have unique physicochemical properties which make them promising platforms for drug delivery. However, immune cells in the bloodstream (such as monocytes, platelets, leukocytes, and dendritic cells) and in tissues (such as resident phagocytes) have a propensity to engulf and eliminate certain nanoparticles. A nanoparticle's interaction with plasma proteins (opsonins) and blood components (via hemolysis, thrombogenicity and complement activation) may influence uptake and clearance and hence potentially affect distribution and delivery to the intended target sites. Nanoparticle uptake by the immune cells is influenced by many factors. Different nanoparticles have been shown to act on different pathways, while various characteristics/properties also affect which pathway is employed for particle internalization. Nanoparticle protein binding occurs almost instantaneously once the particle enters biological medium, and the physical properties of such a particle-protein complex are often different than those of the formulated particle. These new properties can contribute to different biological responses and change nanoparticle biodistribution. Therefore, in the situation when specific delivery to immune cells is not desired, the ideal nanoparticle platform is the one whose integrity is not disturbed in the complex biological environment, which provides extended circulation in the blood to maximize delivery to the target site, is not toxic to blood cellular components, and is "invisible" to the immune cells which can remove it from circulation. This review discusses the most recent data on nanoparticle interactions with blood components and how particle size and surface charge define their hematocompatibility. This includes properties which determine particle interaction with plasma proteins and uptake by macrophages. We will also provide an overview of in vitro methods useful in identifying interactions with components of the immune system and the potential effects of such interaction on particle distribution to tissues.

[1]  E. W. Meijer,et al.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Sabina Passamonti,et al.  Hemolytic effects of water-soluble fullerene derivatives. , 2004, Journal of medicinal chemistry.

[3]  J. Benoit,et al.  Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. , 2006, Journal of biomedical materials research. Part A.

[4]  M. Morandi,et al.  Nanoparticle‐induced platelet aggregation and vascular thrombosis , 2005, British journal of pharmacology.

[5]  M. Frank,et al.  The role of complement in inflammation and phagocytosis. , 1991, Immunology today.

[6]  N. K. Jain,et al.  Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro , 2007, Journal of drug targeting.

[7]  P. Buehler,et al.  Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD163, a scavenger receptor. , 2007, Antioxidants & redox signaling.

[8]  J. B. Hall,et al.  Characterization of nanoparticles for therapeutics. , 2007, Nanomedicine.

[9]  T. Dutta,et al.  Investigations on the toxicological profile of functionalized fifth‐generation poly(propylene imine) dendrimer , 2006, The Journal of pharmacy and pharmacology.

[10]  Takuro Niidome,et al.  PEG-modified gold nanorods with a stealth character for in vivo applications. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[11]  M. Bryszewska,et al.  Influence of PAMAM dendrimers on human red blood cells. , 2004, Bioelectrochemistry.

[12]  Dipak K. Sarker,et al.  Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. , 2006, Journal of nanoscience and nanotechnology.

[13]  Sara Linse,et al.  The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. , 2007, Advances in colloid and interface science.

[14]  H. El-Shall,et al.  Interaction of PLGA nanoparticles with human blood constituents. , 2005, Colloids and surfaces. B, Biointerfaces.

[15]  Hong-Zhuan Chen,et al.  In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[18]  H. Movat,et al.  PLATELET PHAGOCYTOSIS AND AGGREGATION , 1965, The Journal of cell biology.

[19]  J. Alonso-Lebrero,et al.  Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. , 2006, Journal of nanoscience and nanotechnology.

[20]  S. Davis,et al.  Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[21]  A. D. De Groot,et al.  Novel function of complement C3d as an autologous helper T‐cell target , 2008, Immunology and cell biology.

[22]  R. Müller,et al.  Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. , 1996, Journal of drug targeting.

[23]  J. Oh,et al.  Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles , 2005, Pharmaceutical Research.

[24]  J. Cohen,et al.  Apoptosis: the physiologic pathway of cell death. , 1993, Hospital practice.

[25]  R. Müller,et al.  Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  J. Nah,et al.  Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. , 2006, Journal of nanoscience and nanotechnology.

[27]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[28]  Lawrence Tamarkin,et al.  Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.

[29]  L. Yahia,et al.  Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. , 2004, Biomaterials.

[30]  R. Mumper,et al.  Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. , 2002, International journal of pharmaceutics.

[31]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[32]  C. Vauthier,et al.  Complement Activation by Core–Shell Poly(isobutylcyanoacrylate)–Polysaccharide Nanoparticles: Influences of Surface Morphology, Length, and Type of Polysaccharide , 2006, Pharmaceutical Research.

[33]  M. Alonso,et al.  PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[34]  A. Schroit,et al.  In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. , 1985, The Journal of biological chemistry.

[35]  Mark E. Davis,et al.  Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. , 2007, Bioconjugate chemistry.

[36]  R. Eritja,et al.  Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. , 2007, Chemistry.

[37]  T Sakthivel,et al.  DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. , 2000, International journal of pharmaceutics.

[38]  N. M. Khazenzon,et al.  Nanoconjugate based on polymalic acid for tumor targeting. , 2008, Chemico-biological interactions.

[39]  K. Higaki,et al.  Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.

[40]  A. Zahr,et al.  Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). , 2006, Langmuir : the ACS journal of surfaces and colloids.